Sinopharm Group Co (1099) AI Stock Analysis

• Market Cap: $56.70B
• Dividend Yield: 4.06%
• Average Volume (3M): 6.08M
• Price to Earnings (P/E): 7.8
• Beta (1Y): 0.78
• Revenue Growth: -2.68%
• EPS Growth: -21.45%
• Country: HK
• Employees: 108,217
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Distribution
• EPS (TTM): 0.70
• Shares Outstanding: 1,341,810,800
• 10 Day Avg. Volume: 6,381,523
• 30 Day Avg. Volume: 6,082,953
• PEG Ratio: N/A
• Price to Book (P/B): 0.00
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: 3.51
• Enterprise Value/Revenue: 0.34
• Enterprise Value/Gross Profit: 4.49
• Enterprise Value/Ebitda: 9.86
• 1Y Price Target: $22.49
• Price Target Upside: 23.73% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1

• Rating: 68 Neutral
• Price Target: HK$20.50 ▲(12.76% Upside)

The overall stock score is primarily driven by stable financial performance and attractive valuation metrics. While the technical analysis indicates a lack of strong momentum, the low P/E ratio and high dividend yield suggest potential undervaluation. The absence of earnings call data and corporate events means these factors did not influence the score.

Positive Factors

Negative Factors

Sinopharm Group Co Business Overview & Revenue Model

Company Description

Sinopharm Group Co. Ltd., together with its subsidiaries, engages in the wholesale and retail of pharmaceutical and medical devices and healthcare products in the People's Republic of China. The company operates through four segments: Pharmaceutical Distribution, Medical Devices, Retail Pharmacy, and Other Business. The Pharmaceutical Distribution segment distributes pharmaceutical products to hospitals, other distributors, retail drug stores, and clinics. This segment also offers distribution, logistics, and other value-added services for domestic and international pharmaceutical and healthcare products manufacturers, and other suppliers. The Medical Devices segment distributes medical devices. The Retail Pharmacy segment operates and franchises a network of retail drug stores. As of December 31, 2021, this segment had 10,259 retail pharmacies. The Other Business segment engages in the production and sale of pharmaceutical products, chemical reagents, and laboratory supplies. The company also rents and manages properties; distributes medical instruments, Chinese herbal medicines, antibiotics, and biological products; and offers information technology development and medicine consultation, investment, goods and technology import and export, business consultation, health consultation, medical consultation, market information consultation and investigation, and convention and exhibition services. In addition, it manages medical project investment, consulting, and technology training activities. Sinopharm Group Co. Ltd. has a strategic partnership with I-Mab to enhance its commercial capabilities and commercialization transformation. The company was founded in 2003 and is headquartered in Shanghai, the People's Republic of China. Sinopharm Group Co. Ltd. is a subsidiary of Sinopharm Industrial Investment Co., Ltd.

How the Company Makes Money

Sinopharm Group Co. makes money primarily through its extensive pharmaceutical distribution network, which is one of the largest in China. The company generates revenue by purchasing pharmaceutical products from manufacturers and distributing them to hospitals, clinics, and pharmacies. Retail pharmacy operations also contribute significantly to its revenue stream, with a vast network of retail outlets providing direct sales to consumers. Additionally, Sinopharm earns income from the distribution of medical devices and healthcare equipment. Strategic partnerships with international pharmaceutical companies further enhance its product offerings and market reach, contributing to its earnings. The company's large-scale operations and efficient supply chain management play crucial roles in maintaining profitability and revenue growth.

Sinopharm Group Co Financial Statement Overview

Summary

Sinopharm Group Co exhibits stable revenue growth with solid EBITDA margins, though profit margins are under pressure. The balance sheet shows a strong asset base but potential risks with liabilities. Cash flows are generally healthy, but free cash flow variability suggests some strategic adjustments are needed.

Income Statement

The company has shown stable revenue growth over the years, with the revenue growing from 425,272,726,000 in 2019 to 584,507,930,000 in 2024. The gross profit margin has slightly decreased over time, indicating a squeeze on profit margins. The net profit margin has also seen a decline, suggesting that the company is facing increased costs or lower operational efficiency. However, EBITDA margins remain relatively stable, indicating solid core operational performance.

Balance Sheet

The balance sheet shows a high level of total assets and stockholders' equity, reflecting strong capital structure. The debt-to-equity ratio is moderate, suggesting manageable leverage levels. However, the equity ratio has remained somewhat flat, indicating potential risks if liabilities increase sharply. Return on equity has shown variability, which might point to inconsistent profitability.

Cash Flow

Cash flow analysis reveals that the company has had a consistent operating cash flow, although there is a noticeable decline in free cash flow from 2023 to 2024. The operating cash flow to net income ratio shows the company is generating a healthy amount of cash relative to its net income. However, free cash flow growth has been inconsistent, which could indicate challenges in managing capital expenditures or financing activities.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	584.51B	596.57B	552.15B	521.05B	456.41B
Gross Profit	44.26B	48.51B	47.43B	44.05B	40.32B
EBITDA	20.17B	26.90B	26.25B	24.68B	22.62B
Net Income	7.05B	9.05B	14.35B	13.06B	12.10B
Balance Sheet
Total Assets	392.83B	383.39B	364.78B	335.41B	311.24B
Cash, Cash Equivalents and Short-Term Investments	54.31B	63.81B	55.22B	43.54B	50.22B
Total Debt	76.39B	73.78B	69.59B	68.37B	68.53B
Total Liabilities	266.14B	263.08B	254.71B	235.76B	221.29B
Stockholders Equity	78.88B	74.58B	68.07B	61.89B	56.36B
Cash Flow
Free Cash Flow	9.58B	14.84B	18.55B	7.05B	9.07B
Operating Cash Flow	11.55B	17.17B	20.96B	9.31B	11.15B
Investing Cash Flow	-3.75B	-944.53M	-3.59B	-1.27B	-2.20B
Financing Cash Flow	-17.29B	-7.64B	-5.69B	-14.69B	2.03B

Sinopharm Group Co Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 18.18
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:1099, the sentiment is Negative. The current price of 18.18 is below the 20-day moving average (MA) of 18.61, below the 50-day MA of 18.96, and below the 200-day MA of 18.77, indicating a bearish trend. The MACD of -0.17 indicates Positive momentum. The RSI at 36.40 is Neutral, neither overbought nor oversold. The STOCH value of 21.48 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:1099.

Sinopharm Group Co Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
2607	72 Outperform	75.85B	6.80	6.35%	2.64%	3.60%	47.33%
1099	68 Neutral	$56.70B	7.80	8.74%	4.06%	-2.68%	-21.45%
1931	65 Neutral	14.56B	77.41	7.01%	1.02%	0.33%	-44.28%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Sinopharm Group Co Corporate Events

Sinopharm Reports Decline in H1 2025 Financial Performance

Sinopharm Group Co. Ltd. announced the unaudited financial results for its subsidiary, Sinopharm Accord, for the first half of 2025. The company reported a slight decrease in revenue by 2.62% to RMB 36.8 billion and a 10.43% drop in net profit attributable to shareholders. The net cash flow from operating activities significantly declined by 98.38%, indicating potential operational challenges. Despite these declines, total assets increased by 6.04%, reflecting some growth in asset base. The announcement may impact stakeholders’ perception of the company’s financial health and operational efficiency.

The most recent analyst rating on (HK:1099) stock is a Buy with a HK$20.50 price target. To see the full list of analyst forecasts on Sinopharm Group Co stock, see the HK:1099 Stock Forecast page.

Sinopharm Group Reports Decline in 2025 Interim Results

Sinopharm Group Co. Ltd. has announced its unaudited interim results for the first half of 2025, showing a decrease in revenue and profit compared to the same period last year. Despite a reduction in costs, the company experienced a decline in gross profit and operating profit, reflecting challenges in maintaining its financial performance amidst market conditions.

The most recent analyst rating on (HK:1099) stock is a Buy with a HK$22.50 price target. To see the full list of analyst forecasts on Sinopharm Group Co stock, see the HK:1099 Stock Forecast page.

Sinopharm’s CNMDC Reports Mixed Financial Results for H1 2025

Sinopharm Group Co., Ltd. has released the unaudited financial data for its subsidiary, China National Medical Device Co., Ltd. (CNMDC), for the first half of 2025. The report shows a slight decline in revenue and operating profit compared to the previous year, with revenue down by 1.48% and operating profit by 8.28%. However, total comprehensive income attributable to the parent company saw a marginal increase of 1.02%. Notably, the net cash flow from operating activities improved significantly, reducing the deficit by 67.88%. The company’s total assets and equity attributable to owners also saw growth, indicating a stable financial position despite the challenges. This financial update may impact stakeholders’ perceptions of CNMDC’s market positioning and operational efficiency.

The most recent analyst rating on (HK:1099) stock is a Buy with a HK$21.50 price target. To see the full list of analyst forecasts on Sinopharm Group Co stock, see the HK:1099 Stock Forecast page.

Sinopharm Reports Mixed Financial Results for First Half of 2025

Sinopharm Group Co. Ltd. announced its unaudited financial results for the first half of 2025, revealing a slight decrease in total assets by 0.37% and a modest increase in net assets attributable to shareholders by 2.02%. Revenue grew by 3.54% compared to the same period last year, while total profit and net profit attributable to shareholders declined by 6.92% and 5.19% respectively. The company also reported a negative net cash flow from operating activities, indicating potential cash management challenges. These financial indicators suggest a mixed performance, with growth in revenue but a decline in profitability, which may impact the company’s market positioning and stakeholder confidence.

The most recent analyst rating on (HK:1099) stock is a Buy with a HK$21.50 price target. To see the full list of analyst forecasts on Sinopharm Group Co stock, see the HK:1099 Stock Forecast page.

Sinopharm Accord Reports Slight Revenue Decline in H1 2025

Sinopharm Group Co. Ltd. announced preliminary financial results for its subsidiary, Sinopharm Accord, for the first half of 2025, showing a slight decline in revenue and profit compared to the same period last year. Despite a decrease in net profit and earnings per share, the company’s total assets and equity attributable to shareholders saw an increase, indicating a stable financial position amidst challenging market conditions.

The most recent analyst rating on (HK:1099) stock is a Buy with a HK$29.30 price target. To see the full list of analyst forecasts on Sinopharm Group Co stock, see the HK:1099 Stock Forecast page.

Sinopharm Group Schedules Board Meeting to Review Interim Results

Sinopharm Group Co. Ltd. has announced that its board of directors will meet on August 22, 2025, to consider and approve the unaudited interim results for the first half of the year. This meeting is crucial as it will provide insights into the company’s financial performance and strategic direction, potentially impacting its market positioning and stakeholder interests.

The most recent analyst rating on (HK:1099) stock is a Buy with a HK$29.30 price target. To see the full list of analyst forecasts on Sinopharm Group Co stock, see the HK:1099 Stock Forecast page.